Here, we advanced such a strategy using (i) a safe, nonviral biodegradable delivery vehicle that preferentially transfects HCC, (ii) an AFP promoter for transcriptional targeting of HCC, and (iii) completely CpG-free plasmids to reduce TLR9 activation. The gene discussed is AFP; the disease is hepatocellular carcinoma.